OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets
Helmut Butzkueven, Nicholas Moore, Aida Aydemir, et al.
Current Medical Research and Opinion (2022) Vol. 38, Iss. 7, pp. 1167-1176
Open Access | Times Cited: 6
Helmut Butzkueven, Nicholas Moore, Aida Aydemir, et al.
Current Medical Research and Opinion (2022) Vol. 38, Iss. 7, pp. 1167-1176
Open Access | Times Cited: 6
Showing 6 citing articles:
Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan: Fiscal Years 2011–2020
Kazuo Nakamichi, Yoshiharu Miura, Toshio Shimokawa, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 968-968
Open Access | Times Cited: 9
Kazuo Nakamichi, Yoshiharu Miura, Toshio Shimokawa, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 968-968
Open Access | Times Cited: 9
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1457-1476
Open Access | Times Cited: 8
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 5, pp. 1457-1476
Open Access | Times Cited: 8
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
Wallace Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104791-104791
Open Access | Times Cited: 6
Wallace Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104791-104791
Open Access | Times Cited: 6
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Helmut Butzkueven, Jan Hillert, Merja Soilu‐Hänninen, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 10, pp. 1367-1374
Open Access | Times Cited: 3
Helmut Butzkueven, Jan Hillert, Merja Soilu‐Hänninen, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 10, pp. 1367-1374
Open Access | Times Cited: 3
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
Jan Hillert, Helmut Butzkueven, Melinda Magyari, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 717-732
Open Access
Jan Hillert, Helmut Butzkueven, Melinda Magyari, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 717-732
Open Access
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1015-1038
Open Access
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1015-1038
Open Access
